Isomorphic Labs, the Google-backed drug discovery company built on top of DeepMind's Nobel Prize-winning AlphaFold AI, raised $2.1 billion on May 12 — one of the largest funding rounds ever for an AI-driven biotech.
The money lands at a turning point for the company, which has spent the past year pushing its first AI-designed drug candidates toward human clinical trials. Its founder, Demis Hassabis, has spent 2026 arguing that AlphaFold is just the opening move in a much bigger AI-powered scientific revolution.
From Protein Puzzle to Pharma Pipeline
AlphaFold solved a problem biologists had wrestled with for 50 years: predicting the three-dimensional shape of proteins from their amino acid sequence. Knowing a protein's shape tells you where drugs can bind to it, and that opens the door to designing targeted therapies for diseases ranging from cancer to neurodegeneration.
The AI's impact was so significant that Hassabis and AlphaFold lead John Jumper shared the 2024 Nobel Prize in Chemistry with University of Washington biochemist David Baker.
Isomorphic Labs was spun out of DeepMind in 2021 to turn AlphaFold's structural insights into actual medicines. Until now, it has worked largely through partnerships — multibillion-dollar deals signed in 2024 with Novartis and Eli Lilly to design candidate drugs for diseases the pharma giants picked. With the new funding, Isomorphic plans to push more of its own internal pipeline into clinical trials, including programs in oncology and immunology.
What $2.1 Billion Actually Buys
Drug discovery is expensive even when AI does the heavy modeling. Wet labs need to synthesize candidate molecules, run them through cell and animal studies, and then guide them through human safety trials — a process that historically takes a decade and burns through hundreds of millions of dollars per drug.
The Isomorphic bet is that AlphaFold-class models can compress the early stages dramatically. By predicting how candidate molecules will bind to target proteins before any chemistry is done, the company can throw out bad designs in software instead of in the lab, and concentrate experimental resources on candidates that look most likely to work.
The $2.1 billion gives the company runway to expand its compute infrastructure, hire across structural biology and medicinal chemistry, and crucially, fund the late-preclinical and Phase 1 trials where AI-designed drugs will be judged not by their elegance but by whether they help patients.
A Watershed Moment
Industry analysts have called 2026 a watershed year for AI in pharma — the moment when AlphaFold-era models stop being curiosities and start producing molecules being tested in real human bodies. Isomorphic Labs is the company most directly positioned to ride that transition.
Hassabis has been blunt about the ambition. AlphaFold, in his framing, is the first rung. The full ladder leads to a future where AI doesn't just speed up science — it routinely originates discoveries that human researchers would never have found on their own.
With $2.1 billion in the bank and the first Isomorphic-designed molecules heading into trials, the next few years should tell us whether the ladder actually climbs.
